Abstract
Although fungal infections contribute substantially to human morbidity and mortality, the impact of these diseases on human health is not widely appreciated. Diagnosis and treatment of fungal infections remain a challenge in medicine despite recent major advances. The search for novel pharmacological compounds with antifungal action is a real requirement. Taking it into consideration, research groups have investigated the effects of aspartic peptidase inhibitors (PIs) on the development of human fungal pathogens such as Candida spp, mainly Candida albicans and Candida parapsilosis, Cryptococcus neoformans, Pneumocystis jiroveci and Fonsecaea pedrosoi, based on the following premises: (1) this class of hydrolytic enzymes performs multiple relevant roles in pathophysiological events associated to the fungal infections and (2) the introduction of human immunodeficiency virus (HIV) PIs in the clinical arena drastically reduced the opportunistic infections caused by fungi in this population. As expected, the blockage of one of these physiological/pathological processes should help in containing the fungal infection. Corroborating this hypothesis, both in vitro and in vivo studies have reported that classical aspartic PIs (e.g., pepstatin A) as well as HIV PIs (e.g., nelfinavir, saquinavir, ritonavir, indinavir, amprenavir, lopinavir and tipranavir) have induced several cellular and biochemical alterations on fungal cells. Some of the metabolic perturbations are extremely drastic to the fungal cells, which culminate in arresting nutrition, growth, proliferation, differentiation, adhesion, invasion and dissemination. In the present chapter, we will describe the beneficial effects of aspartic PIs against some human fungal pathogens, reporting in details their mechanisms capable in disturbing the fungal homeostasis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Reiss E, Shadomy HJ, Lyon GM (2011) Fundamental medical mycology. Wiley-Blackwell, London
Pfaller MA, Pappas PG, Wingard JR (2006) Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 43:S3–S14
Fisher MC, Henk DA, Briggs CJ et al (2012) Emerging fungal threats to animal, plant and ecosystem health. Nature 484:186–194
Martin GS, Mannino DM, Eaton S et al (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546–1554
Horn F, Heinekamp T, Kniemeyer O et al (2012) Systems biology of fungal infection. Front Microbiol 3:108
Nucci M, Marr KA (2005) Emerging fungal diseases. Clin Infect Dis 41:521–526
Enoch DA, Ludlam HA, Brown NM (2006) Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 55:809–818
Fera MT, La Camera E, De Sarro A (2009) New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther 7:981–998
Chian-Yong L, Rotstein C (2011) Emerging fungal infections in immunocompromised patients. Med Rep 3:14
Miceli MH, Díaz JA, Lee AS (2011) Emerging opportunistic yeast infections. Lancet Infect Dis 11:142–151
Pfaller MA, Diekema DJ (2004) Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 42:4419–4431
Marr KA, Carter RA, Crippa F et al (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34:909–917
Perfect JR (2004) Use of newer antifungal therapies in clinical practice: what do the data tell us? Oncology 18:15–23
Sable CA, Strohmaier KM, Chodakewitz JA (2008) Advances in antifungal therapy. Annu Rev Med 59:361–379
Petrikkos G, Skiada A (2007) Recent advances in antifungal chemotherapy. Int J Antimicrob Agents 30:108–117
Naeger-Murphy N, Pile JC (2009) Clinical indications for newer antifungal agents. J Hosp Med 4:102–111
Chen SC, Playford EG, Sorrell TC (2010) Antifungal therapy in invasive fungal infections. Curr Opin Pharmacol 10:522–530
Gupta AK, Tomas E (2003) New antifungal agents. Dermatol Clin 21:565–576
Lai CC, Tan CK, Huang YT et al (2008) Current challenges in the management of invasive fungal infections. J Infect Chemother 14:77–85
Pemán J, Cantón E, Espinel-Ingroff A (2009) Antifungal drug resistance mechanisms. Expert Rev Anti Infect Ther 7:453–460
Kathiravan MK, Salake AB, Chothe AS et al (2012) The biology and chemistry of antifungal agents: a review. Bioorg Med Chem 20:5678–5698
Gubbins PO, Anaissie EJ (2009) Antifungal therapy. In: Anaissie EJ, McGinnis MR, Pfaller MA (eds) Clinical mycology, 2nd edn. Elsevier, New York, pp 161–197
Karkowska-Kuleta J, Rapala-Kozik M, Kozik A (2009) Fungi pathogenic to humans: molecular bases of virulence of Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus. Acta Biochim Pol 56:211–224
Espinel-Ingroff A (2009) Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005–2009). Rev Iberoam Micol 26:15–22
Butts A, Krysan DJ (2012) Antifungal drug discovery: something old and something new. PLoS Pathog 8:e1002870
Mehra T, Köberle M, Braunsdorf C et al (2012) Alternative approaches to antifungal therapies. Exp Dermatol 21:778–782
Hube B (2000) Extracellular peptidases of human pathogenic fungi. Contrib Microbiol 5:126–137
Santos ALS (2010) HIV aspartyl protease inhibitors as promising compounds against Candida albicans. World J Biol Chem 1:21–30
Santos ALS (2010) Aspartic peptidase inhibitors as potential bioactive pharmacological compounds against human fungal pathogens. In: Ahmad I, Owais M, Shahid M, Aqil F (eds) Combating fungal infections: problems and remedy, 1st edn. Springer, Heidelberg, pp 289–326
Santos ALS (2011) Protease expression by microorganisms and its relevance to crucial physiological/pathological events. World J Biol Chem 2:48–58
Santos ALS (2011) Aspartic proteases of human pathogenic fungi are prospective targets for the generation of novel and effective antifungal inhibitors. Curr Enz Inhib 7:96–118
TurK B (2006) Targeting proteases: successes, failures and future prospects. Nat Rev 5:785–799
López-Otín C, Overall CM (2002) Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 3:509–519
Ehrmann M, Clausen T (2004) Proteolysis as a regulatory mechanism. Annu Rev Genet 38:709–724
Sauer RT, Bolon DN, Burton BM et al (2004) Sculpting the proteome with AAA+ proteases and disassembly machines. Cell 119:9–18
Siegel RM (2006) Caspases at the crossroads of immune-cell life and death. Nat Rev Immunol 6:308–317
Oikonomopoulou K, Hansen KK, Saifeddine M et al (2006) Proteinase-mediated cell signaling: targeting proteinase-activated receptors (PARs) by kallikreins and more. Biol Chem 387:677–685
Urban S (2006) Rhomboid proteins: conserved membrane proteases with divergent biological functions. Genes Dev 20:3054–3068
Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases and the regulation of tissue remodeling. Nat Rev Mol Cell Biol 8:221–233
Marino G, Uria JA, Puente X et al (2003) Human autophagins, a family of cysteine proteinases potentially implicated in cell degradation by autophagy. J Biol Chem 278:3671–3678
Ciechanover A (2005) Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6:79–87
López-Otín C, Bond JS (2008) Proteases: multifunctional enzymes in life and disease. J Biol Chem 283:30433–30437
Perona J, Craik CS (1995) Structural basis of substrate specificity in the serine proteases. Protein Sci 4:337–360
Gillmor SA, Craick CS, Fletterick RJ (1997) Structural determinants of specificity in the cysteine protease cruzain. Protein Sci 6:1603–1611
Sajid M, Mckerrow JH (2002) Cysteine proteases of parasitic organisms. Mol Biochem Parasitol 120:1–21
Garcia-Touchard A, Henry TD, Sangiorgi G et al (2005) Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol 25:1119–1127
Maupin-Furlow JA, Gil MA, Humbard MA et al (2005) Archaeal proteasomes and other regulatory proteases. Curr Opin Microbiol 8:720–728
Diamond SL (2007) Methods for mapping protease specificity. Curr Opin Chem Biol 11:46–51
Otto HH, Schirmeister T (1997) Cysteine proteases and their inhibitors. Chem Rev 97:133–171
Vandeputte-Rutten L, Gros P (2002) Novel proteases: common themes and surprising features. Curr Opin Struct Biol 12:704–708
Rao MB, Tanksale AM, Ghatge MS et al (1998) Molecular and biotechnological aspects of microbial proteases. Microbiol Mol Biol Rev 62:597–635
Barrett AJ, Rawlings ND, O’Brien EA (2001) The MEROPS database as a protease information system. J Struct Biol 134:95–102
Barrett AJ, Tolle DP, Rawlings ND (2003) Managing peptidases in the genomic era. Biol Chem 384:873–882
Rawlings ND, Tolle DP, Barrett AJ (2004) Evolutionary families of peptidase inhibitors. Biochem J 378:705–716
Rawlings ND, Morton FR, Barrett AJ (2006) MEROPS: the peptidase database. Nucleic Acids Res 34:D270–D272
Schechter I, Berger A (1967) On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27:157–162
Rawlings ND, Barrett AJ, Baterman A (2012) MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res 40:D343–D350
James MNG, Sielecki A, Saliturot F et al (1982) Conformational flexibility in the active sites of aspartyl proteinases revealed by a pepstatin fragment binding to penicillopepsin. Proc Natl Acad Sci U S A 79:6137–6141
Hyland LJ, Tomaszek TA, Meek TD (1991) Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry 30:8454–8463
Tossi A, Bonin I, Antcheva N et al (2000) Aspartic protease inhibitors. An integrated approach for the design and synthesis of diaminodiol based peptidomimetics. Eur J Biochem 267:1715–1722
Davies DR (1990) The structure and function of the aspartic proteinases. Annu Rev Biophys Chem 19:189–215
Blundell TL, Johnson MS (1993) Catching a common fold. Protein Sci 2:877–883
Coates L, Erskine PT, Mall S et al (2006) X-ray, neutron and NMR studies of the catalytic mechanism of aspartic proteinases. Eur Biophys J 35:559–566
Umezawa H, Aoyagi T, Morishima H et al (1970) Pepstatin, a new peptide inhibitor produced by actinomycetes. J Antibiotics 23:259–262
Koelsch G, Mares M, Metcalf P et al (1994) Multiple functions of pro-parts of aspartic proteinase zymogens. FEBS Lett 343:6–10
Foltmann B (1988) Structure and function of proparts in zymogens for aspartic proteinases. Biol Chem 369:311–314
Hill J, Phylip L (1997) Bacterial aspartic proteinases. FEBS Lett 409:357–360
Dash C, Kulkarni A, Dunn B et al (2003) Aspartic peptidase inhibitors: implications in drug development. Crit Rev Biochem Mol Biol 38:89–119
Cooper JB (2002) Aspartic proteinases in disease: a structural perspective. Curr Drug Targets 3:155–173
Fruton J (2002) A history of pepsin and related enzymes. Quart Rev Biol 77:127–147
Sielecki R, Fujinanga M, Read RJ et al (1991) Refined structure of porcine pepsinogenat 1.8 Å resolution. J Mol Biol 219:671–692
Suguna K, Padlan EA, Smith CW et al (1987) Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: implications for a mechanism of action. Proc Natl Acad Sci U S A 84:7009–7013
Holm I, Ollo R, Panthier J et al (1984) Evolution of aspartyl proteases by gene duplication: the mouse renin gene is organized in two homologous clusters of four exons. EMBO J 3:557–562
Veerapandian B, Cooper J, Sali A et al (1992) Direct observation by X-ray analysis of the tetrahedral “intermediate” of aspartic proteinases. Protein Sci 1:322–328
Northrop D (2001) Follow the protons: a low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases. Acc Chem Res 34:790–797
Dunn B (2002) Structure and mechanism of the pepsin-like family of aspartic peptidases. Chem Rev 102:4431–4458
Nguyen JT, Hamada Y, Kimura T et al (2008) Design of potent aspartic protease inhibitors to treat various diseases. Arch Pharm Chem Life Sci 341:523–535
Stewart K, Abad-Zapatero C (2001) Candida proteases and their inhibition: prospects for antifungal therapy. Curr Med Chem 8:941–948
Monod M, Capoccia S, Lechenne B et al (2002) Secreted proteases from pathogenic fungi. Int J Med Microbiol 292:405–419
Naglik JR, Challacombe SJ, Hube B (2003) Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 67:400–428
Naglik JR, Albrecht A, Bader O et al (2004) Candida albicans proteinases and host/pathogen interactions. Cell Microbiol 6:915–926
Armstrong PB (2006) Proteases and protease inhibitors: a balance of activities in host-pathogen interaction. Immunobiology 211:263–281
Leung D, Abbenante G, Fairlie DP (2000) Protease inhibitors: current status and future prospects. J Med Chem 43:305–341
Abbenante G, Fairlie DP (2005) Protease inhibitors in the clinic. Med Chem 1:71–104
Eder J, Hommel U, Cumin F et al (2007) Aspartic proteases in drug discovery. Curr Pharm Des 13:271–285
Santos ALS, Braga-Silva LA (2013) Aspartic protease inhibitors: effective drugs against the human fungal pathogen Candida albicans. Mini Rev Med Chem 13:155–162
Braga-Silva LA, Santos ALS (2011) Aspartic protease inhibitors as potential anti–Candida albicans drugs: impacts on fungal biology, virulence and pathogenesis. Curr Med Chem 18: 2401–2419
Wu T, Wright K, Hurst SF et al (2000) Enhanced extracellular production of aspartyl proteinase, a virulence factor, by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole. Antimicrob Agents Chemother 44:1200–1208
Ripeau JS, Aumont F, Belhumeur P et al (2002) Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitro. Antimicrob Agents Chemother 46:3096–3100
Copping VM, Barelle CJ, Hube B et al (2005) Exposure of Candida albicans to antifungal agents affects expression of SAP2 and SAP9 secreted proteinase genes. J Antimicrob Chemother 55:645–654
Navarathna DH, Hornby JM, Hoerrmann N et al (2005) Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis. J Antimicrob Chemother 56:1156–1159
Mores AU, Souza RD, Cavalca L et al (2011) Enhancement of secretory aspartyl protease production in biofilms of Candida albicans exposed to sub-inhibitory concentrations of fluconazole. Mycoses 54:195–201
Dornelas-Ribeiro M, Pinheiro EO, Guerra C et al (2012) Cellular characterisation of Candida tropicalis presenting fluconazole-related trailing growth. Mem Inst Oswaldo Cruz 107:31–38
Bode W, Huber R (2000) Structural basis of the endoproteinase protein inhibitor interaction. Biochim Biophys Acta 1477:241–252
Babiker A, Darbyshire J, Pezzotti P et al (2002) Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks. Int J Epidemiol 31:951–958
Hoegl L, Thoma-Greber E, Röcken M et al (1998) HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: results of a study over a period of 2 years. Mycoses 41:321–325
Mirza SA, Phelan M, Rimland D et al (2000) The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 36:789–794
Morris A, Lundgren JD, Masur H et al (2004) Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 10:1713–1720
Tellez I, Barragan M, Franco-Paredes C et al (2008) Pneumocystis jiroveci pneumonia in patients with AIDS in the inner city: a persistent and deadly opportunistic infection. Am J Med Sci 335:192–197
Ghannoum M, Abu Elteen K (1986) Correlative relationship between proteinase production, adherence and pathogenicity of various strains of Candida albicans. J Med Vet Mycol 24:407–413
Cassone A, De Bernardis F, Mondello F et al (1987) Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Infect Dis 156:777–783
Kobayashi I, Kondoh Y, Shimizu K, Tanaka K et al (1989) A role of secreted proteinase of Candida albicans for the invasion of chick chorioallantoic membrane. Microbiol Immunol 33:709–719
Louie A, Dixon DM, El-Maghrabi EA et al (1994) Relationship between Candida albicans epidermolytic proteinase activity and virulence in mice. J Med Vet Mycol 32:59–64
De Bernardis F, Sullivan PA, Cassone A (2001) Aspartyl proteinases of Candida albicans and their role in pathogenicity. Med Mycol 39:303–313
Palmeira VF, Kneipp LF, Alviano CS et al (2006) Secretory aspartyl peptidase from mycelia of Fonsecaea pedrosoi: effect of HIV peptidase inhibitors. Res Microbiol 157:819–826
Palmeira VF, Kneipp LF, Alviano CS et al (2006) The major chromoblastomycosis fungal pathogen Fonsecaea pedrosoi extracellularly releases proteolytic enzymes whose expression is modulated by culture medium composition: implications on the fungal development and cleavage of key’s host structures. FEMS Immunol Med Microbiol 46:21–29
Palmeira VF, Kneipp LF, Rozental S et al (2008) Beneficial effects of HIV aspartyl peptidase inhibitors on the human pathogen Fonsecaea pedrosoi: promising compounds to arrest key fungal biological process and virulence. PLoS ONE 3:e3382
Borg von Zepelin M, Meyer I, Thomssen R et al (1999) HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases. J Invest Dermatol 113:747–751
Korting HC, Schaller M, Eder G et al (1999) Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemother 43:2038–2042
Cassone A, De Bernardis F, Torosantucci A et al (1999) In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 180:448–453
Braga-Silva LA, Mogami SS, Valle RS et al (2010) Multiple effects of amprenavir against Candida albicans. FEMS Yeast Res 10:221–224
Skrbec D, Romeo D (2002) Inhibition of Candida albicans secreted aspartic protease by a novel series of peptidomimetics, also active on the HIV-1 protease. Biochem Biophys Res Commun 297:1350–1353
Pichova I, Pavlickova L, Dostal J et al (2001) Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors. Eur J Biochem 268:2669–2677
Hrusková-Heidingsfeldová O, Dostál J, Majer F et al (2009) Two aspartic proteinases secreted by the pathogenic yeast Candida parapsilosis differ in expression pattern and catalytic properties. Biol Chem 390:259–268
Blasi E, Colombari B, Orsi CF et al (2004) The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen Cryptococcus neoformans. FEMS Immunol Med Microbiol 42:187–195
Pinti M, Orsi CF, Gibellini L et al (2007) Identification and characterization of an aspartyl protease from Cryptococcus neoformans. FEBS Lett 581:3882–3886
Calugi C, Guarna A, Trabocchi A (2013) Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors. J Enzyme Inhib Med Chem 28(5):936–943
Calugi C, Trabocchi A, De Bernardis F et al (2012) Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from Candida albicans reveal a constrained inhibitory chemotype. Bioorg Med Chem 20:7206–7213
Pranav Kumar SK, Kulkarni VM (2002) Insights into the selective inhibition of Candida albicans secreted aspartyl protease: a docking analysis study. Bioorg Med Chem 10:1153–1170
Antipov E, Cho AE, Wittrup KD et al (2008) Highly L and D enantioselective variants of horseradish peroxidase discovered by an ultrahigh-throughput selection method. Proc Natl Acad Sci U S A 105:17694–17699
Harriman DJ, Lambropoulos A, Deslongchamps G (2007) In silico correlation of enantioselectivity for the TADDOL catalyzed asymmetric hetero-Diels-Alder reaction. Tetrahedron Lett 48:689–692
Hermann JC, Ghanem E, Li Y et al (2006) Predicting substrates by docking high-energy intermediates to enzyme structures. J Am Chem Soc 128:15882–15891
Soares TA, Goodsell D, Ferreira R et al (2000) Ionization state and molecular docking studies for the macrophage migration inhibitory factor: the role of lysine 32 in the catalytic mechanism. J Mol Recognit 13:146–156
Soares TA, Goodsell DS, Briggs JM et al (1999) Docking of 4-oxalocrotonate tautomerase substrates: implications for the catalytic mechanism. Biopolymers 50:319–328
Brooijmans N, Kuntz ID (2003) Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct 32:335–373
Huang SY, Zou X (2007) Ensemble docking of multiple protein structures: considering protein structural variations in molecular docking. Proteins 66:399–421
Jorgensen WL (2009) Efficient drug lead discovery and optimization. Acc Chem Res 42:724–733
Mohan V, Gibbs AC, Cummings MD et al (2005) Docking: successes and challenges. Curr Pharm Des 11:323–333
Kempf DJ, Marsh KC, Denissen JF et al (1995) ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A 92:2484–2488
Roberts NA, Martin JA, Kinchington D et al (1990) Rational design of peptide-based HIV proteinase inhibitors. Science 248:358–361
Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14:33–38
Gruber A, Speth C, Lukasser-Vogl E et al (1999) Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro. Immunopharmacology 41:227–234
Gruber A, Berlit J, Speth C et al (1999) Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors. Immunobiology 201:133–144
Schaller M, Krnjaic N, Niewerth M et al (2003) Effect of antimycotic agents on the activity of aspartyl proteinases secreted by Candida albicans. J Med Microbiol 52:247–249
Blanco MT, Hurtado C, Pérez-Giraldo C et al (2003) Effect of ritonavir and saquinavir on Candida albicans growth rate and in vitro activity of aspartyl proteinases. Med Mycol 41:167–170
Santos ALS, Carvalho IM, Silva BA et al (2006) Secretion of serine peptidase by a clinical strain of Candida albicans: influence of growth conditions and cleavage of human serum proteins and extracellular matrix components. FEMS Immunol Med Microbiol 46:209–220
Dostál J, Hamal P, Pavlícková L et al (2003) Simple method for screening Candida species isolates for the presence of secreted proteinases: a tool for the prediction of successful inhibitory treatment. J Clin Microbiol 41:712–716
Asencio MA, Garduño E, Pérez-Giraldo C et al (2005) Exposure to therapeutic concentrations of ritonavir, but not saquinavir, reduces secreted aspartyl proteinase of Candida parapsilosis. Chemotherapy 51:252–255
Monari C, Pericolini E, Bistoni G et al (2005) Influence of indinavir on virulence and growth of Cryptococcus neoformans. J Infect Dis 191:307–311
Atzori C, Angeli E, Mainini A et al (2000) In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii. J Infect Dis 181:1629–1634
Atzori C, Villani P, Regazzi M et al (2003) Detection of intrapulmonary concentration of lopinavir in an HIV infected patient. AIDS 17:1710–1711
Walzer PD, Ashbaugh A, Collins M et al (2001) Antihuman immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo. J Infect Dis 184:1355–1357
Fantoni G, Atzori C, Tronconi E et al (2004) HIV protease inhibitors and Pneumocystis. J Eukaryot Microbiol 51:376–377
Mazza F, Tronconi E, Valerio A et al (2006) The non-peptidic HIV protease inhibitor tipranavir and two synthetic peptidomimetics (TS98 and TS102) modulate Pneumocystis carinii growth and proteasome activity of HEL299 cell line. J Eukaryot Microbiol 53:S144–S146
Moms A, Wachter RM, Luce J et al (2003) Improved survival with highly active antiretroviral therapy in HIV infected patients with severe Pneumocystis carinii pneumonia. AIDS 17:73–80
Van Burik JA, Magee PT (2001) Aspects of fungal pathogenesis in humans. Annu Rev Microbiol 55:743–772
Casadevall A, Pirofski LA (2009) Virulence factors and their mechanisms of action: the view from a damage-response framework. J Water Health 7(Suppl 1):S2–S18
Gow NA, van de Veerdonk FL, Brown AJ et al (2011) Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nat Rev Microbiol 10:112–122
Wang L, Lin X (2012) Morphogenesis in fungal pathogenicity: shape, size, and surface. PLoS Pathog 12:e1003027
Jacobsen ID, Wilson D, Wächtler B et al (2012) Candida albicans dimorphism as a therapeutic target. Expert Rev Anti Infect Ther 10:85–93
Berman J (2006) Morphogenesis and cell cycle progression in Candida albicans. Curr Opin Microbiol 9:595–601
Peberdy JF (1994) Protein secretion in filamentous fungi—trying to understand a highly productive black box. Trends Biotechnol 2:50–57
Bouws H, Wattenberg A, Zorn H (2008) Fungal secretomes–nature’s toolbox for white biotechnology. Appl Microbiol Biotechnol 3:381–388
Hruskova-Heidingsfeldova O (2008) Secreted proteins of Candida albicans. Front Biosci 13:7227–7242
Consolaro ME, Gasparetto A, Svidzinski TI et al (2006) Effect of pepstatin A on the virulence factors of Candida albicans strains isolated from vaginal environment of patients in three different clinical conditions. Mycopathologia 162:75–82
Cenci E, Francisci D, Belfiori B et al (2008) Tipranavir exhibits different effects on opportunistic pathogenic fungi. J Infect 56:58–64
De Bernardis F, Tacconelli E, Mondello F et al (2004) Anti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo by Candida albicans without selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility. FEMS Immunol Med Microbiol 1:27–34
Gow NA, Hube B (2012) Importance of the Candida albicans cell wall during commensalism and infection. Curr Opin Microbiol 4:406–412
O’Meara TR, Alspaugh JA (2012) The Cryptococcus neoformans capsule: a sword and a shield. Clin Microbiol Rev 3:387–408
Tsang CS, Hong I (2010) HIV protease inhibitors differentially inhibit adhesion of Candida albicans to acrylic surfaces. Mycoses 53:488–494
Ollert MW, Sohnchen R, Korting HC et al (1993) Mechanisms of adherence of Candida albicans to cultured human epidermal keratinocytes. Infect Immun 61:4560–4568
Bektic J, Lell CP, Fuchs A et al (2001) HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro. FEMS Immunol Med Microbiol 31:65–71
Falkensammer B, Pilz G, Bektic J et al (2007) Absent reduction by HIV protease inhibitors of Candida albicans adhesion to endothelial cells. Mycoses 50:172–177
Borg von Zepelin M, Beggah S, Boggian K et al (1998) The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages. Mol Microbiol 28:543–554
Cuéllar-Cruz M, López-Romero E, Villagómez-Castro JC et al (2012) Candida species: new insights into biofilm formation. Future Microbiol 6:755–771
Osherov N, May GS (2001) The molecular mechanisms of conidial germination. FEMS Microbiol Lett 199:153–160
De Bernardis F, Boccanera M, Adriani D et al (1997) Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 65:3399–3405
De Bernardis F, Mondello F, Scaravelli G et al (1999) High aspartyl proteinase production and vaginitis in human immunodeficiency virus-infected women. J Clin Microbiol 37:1376–1380
Edison AM, Manning-Zweerink M (1988) Comparison of the extracellular proteinase activity produced by a low-virulence mutant of Candida albicans and its wild-type parent. Infect Immun 56:1388–1390
Fallon K, Bausch K, Noonan J et al (1997) Role of aspartic proteases in disseminated Candida albicans infection in mice. Infect Immun 65:551–556
Rüchel R, Ritter B, Schaffrinski M (1990) Modulation of experimental systemic murine candidosis by intravenous pepstatin. Zentralbl Bakteriol 273:391–403
Zotter C, Haustein UF, Schonborn C et al (1990) Effect of pepstatin A on Candida albicans infection in the mouse. Dermatol Monatsschr 176:189–198
Acknowledgements
This study was supported by grants from the Brazilian Agencies: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Amparo à Pesquisa no Estado do Rio de Janeiro (FAPERJ), Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho de Ensino e Pesquisa para Graduados da Universidade Federal do Rio de Janeiro (CEPG-UFRJ), Fundação Oswaldo Cruz (FIOCRUZ), Fundação de Amparo à Ciência do Estado de Pernambuco (FACEPE), NanoBiotec-BR and INCT-INAMI. André L.S. Santos was supported by CNPq and FAPERJ fellowships.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Santos, A.L.S. et al. (2013). Aspartic Proteolytic Inhibitors Induce Cellular and Biochemical Alterations in Fungal Cells. In: Chakraborti, S., Dhalla, N. (eds) Proteases in Health and Disease. Advances in Biochemistry in Health and Disease, vol 7. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9233-7_7
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9233-7_7
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-9232-0
Online ISBN: 978-1-4614-9233-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)